XML 20 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaborative Arrangements and Licensing Agreements (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 6 Months Ended 6 Months Ended
Jun. 30, 2012
Xenon Pharmaceuticals Inc.
Development milestones
Jun. 30, 2012
Xenon Pharmaceuticals Inc.
Commercialization milestones
Jun. 30, 2012
Xenon Pharmaceuticals Inc.
Regulatory milestones
Jun. 30, 2012
Xenon Pharmaceuticals Inc.
Pre-specified events
Jun. 30, 2012
Collaborations
Biogen Idec
Jun. 30, 2012
Collaborations
Biogen Idec
Jan. 31, 2012
Collaborations
Biogen Idec
Agreement entered into in January 2012
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in January 2012
Phase 2/3
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in January 2012
Development milestones
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in January 2012
Pre-specified regulatory milestones
Jul. 31, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
IND-enabling toxicology study
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
Development milestones
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
Pre-specified regulatory milestones
May 31, 2012
Collaborations
Genzyme Corporation
Jun. 30, 2008
Collaborations
Genzyme Corporation
Y
Jun. 30, 2012
Collaborations
Genzyme Corporation
Jun. 30, 2011
Collaborations
Genzyme Corporation
Jun. 30, 2012
Collaborations
Genzyme Corporation
D
Jun. 30, 2011
Collaborations
Genzyme Corporation
Dec. 31, 2011
Collaborations
Genzyme Corporation
Jun. 30, 2012
Collaborations
Genzyme Corporation
Minimum
Jun. 30, 2012
Collaborations
Genzyme Corporation
Maximum
Jun. 30, 2012
Collaborations
Genzyme Corporation
Commercialization milestones
Jun. 30, 2012
Collaborations
Genzyme Corporation
Regulatory milestones
Jun. 30, 2012
Collaborations
Genzyme Corporation
Pre-specified events
Jun. 30, 2012
Collaborations
Xenon Pharmaceuticals Inc.
Phase 2
Collaborations                                                        
Maximum value of collaboration agreement             $ 299         $ 271                                
Upfront fee received             29       12                                  
Maximum amount of payments receivable                 45 150       59 130                          
Next prospective milestone               18         10             25               3
Deferred revenue         25.4 25.4                       7.5   7.5   27.7            
Revenue earned         1.8 3.6                       42.8 16.6 59.1 33.2              
License fee received                                 175                      
Equity investment in entity made by strategic alliance partner                                 150                      
Equity investment in entity made by strategic alliance partner (in shares)                                 5                      
Percentage profit                                             30.00% 50.00%        
Milestone payment received                               25                        
Initial development cost contributed                                       125                
Period following an acquisition within which collaborator may purchase rights to receive payments (in days)                                       180                
Isis stock ownership percentage must be less than this percentage for strategic partner to acquire additional Isis common stock without prior consent                                   2.00%   2.00%                
Maximum period additional shares of Isis common stock will not be purchased without consent (in years)                                 10                      
Premium for which amortization was completed during the period                               100                        
License fee for which amortization was completed during the period                               175                        
Percent of total revenue         4.00% 5.00%                       90.00%   84.00%                
Maximum amount of milestone payments receivable under strategic alliance $ 26 $ 120 $ 150 $ 296                                         $ 825 $ 725 $ 1,500